The immune response of immunotherapy in colorectal cancer remains low and new adjuvant targets are in demand. By in vivo CRISPR-Cas9 screening that targets membrane and secreted proteins genes, the authors identify that disrupting MBTPS1 in tumor cells upregulates STAT1-transcribed chemokines, promotes CXCR3+ CD8 T cells infiltration and potentiates anti-PD-1 therapy.
- Yi-Yu Wang
- Jin-Fei Lin
- Rui-Hua Xu